CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis

Clinical Transplantation

Volumn 22, Issue 1, 2008, Pages 89-97

  Bonaros, Nikolaos ^a,b   Mayer, Bernd ^a   Schachner, Thomas ^a   Laufer, Günther ^a   Kocher, Alfred ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b NONE   (Austria)

Author keywords

CMV disease; CMV hyperimmune globulin; CMV infection; CMV prophylaxis; Solid organ transplantation

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; PLACEBO;

ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; COCHRANE LIBRARY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; EMBASE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; INFECTION RISK; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION;

CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 38549099649     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00750.x     Document Type: Article

References (37)

1. Fishman JA. Infection in organ transplant recipients. N Engl J Med 1998: 338: 1741.
2. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000: 13: 83.
3. Valantine HA. Role of CMV in transplant coronary disease and survival after heart transplantation. Transpl Inf Dis 1999: 1 (Suppl. 1): 25.
4. Van den Berg AP, Klompmaker IJ, Hepkema BG et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant 1996: 10: 224.
5. Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 1997: 176: 1462.
6. Rubin RH, Lynch P, Pasternack MS, Schoenfeld D, Medearis DN Jr. Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicorb Agents Chemother 1989: 33: 18975.
7. Falagas ME, Snydman DR, Ruthazer R et al. Cytomegalovirus immune globulin prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997: 11: 432.
8. Valantine HA. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: Evidence for beneficial effect of hyperimmune globulin. Transplant Proc 1995: 27 (Suppl. 1): 49.
9. Bailey TC, Ettinger NA, Storch GA et al. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993: 95: 273.
10. Boland GJ, Ververs C, Hene RJ, Jambroes Donckerwolcke RA, de Gast GC. Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis. Transplant Int 1993: 6: 34.
11. Greger B, Kurth J, Schareck WD, Müller GH, Hopt UT, Bockhorn H. CMV-prophylaxis after kidney transplantation: Is it always suggestive? Immun Infekt 1985: 5: 215.
12. Grundmann R, Wienand P, Runde A, Baldamus CA, Arns W, Burkhardt U. Cytomegalovirus hyperimmunoglobulin prophylaxis following kidney transplantation. Results of a prospective randomized study. Dtsch Med Wochenschr 1987: 112: 827.
13. Kasiske B, Heim-Duthoy KL, Tortorice KL, Ney AL, Odland MD, Rao KV. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch Intern Med 1989: 149: 2733.
14. Metselaar HJ, Rothbarth PH, Brouwer RM, Wenting GJ, Jeekel J, Weimar W. Prevention of cytomegalovirus-related death by passive immunization. Transplantation 1989: 48: 264.
15. Rostaing L, Martinet O, Cisterne JM, Icart J, Chabannier MH, Durand D. CMV Prophylaxis in high-risk renal transplant patients (D+/R-) by acyclovir with or without hyperimmune (CMV) immunoglobulins: A prospective study. Am J Nephrol 1997: 17: 489.
16. Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987: 317: 1049.
17. Snydman WB, Werner BG, Dougherty NN et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double blind, placebo-controlled trial. The Boston Center for liver Transplantation CMVIG Study Group. Ann Intern Med 1993: 119: 984.
18. Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant 2003: 22: 754.
19. Falagas ME, Paya C, Ruthazer R et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation - a prospective derivation and validation cohort analysis. Transplantation 1998: 66: 1020.
20. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989: 261: 3561.
21. Wittes JT, Kelly A, Plante KM. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplant Proc 1996: 28 (6 Suppl. 2): 17.
22. George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation. CMVIG study group. Am J Med 1997: 103: 106.
23. Glowacki LM, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients-a meta-analysis. Clin Transplant 1994: 8: 10.
24. Kocher AA, Bonaros N, Dunkler D et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 2003: 22: 250.
25. Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006: 81: 1415.
26. Bonaros NE, Kocher AA, Dunkler D et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004: 77: 890.
27. Valantine HA, Luikart H, Doyle R et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation. A comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001: 72: 1647.
28. Rowshani AT, Bemelman FJ, Van Leeuwen EMM, Van Lier RAW, Ten Berger IJM. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005: 79: 381.
29. Yadin O, Dewing P, Ma JP, Ettenger RB. Cytomegalovirus hyperimmune gammaglobulin downregulates in vitro T-cell responses. Transplant Proc 1996: 28 (6 Suppl. 2): 7.
30. Sivasai KSR, Mohanakumar T, Phelan D, Martin S, Anstey ME, Brennan DC. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates. Clin Exp Immunol 2000: 119: 559.
31. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005: 143: 870.
32. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005: 365: 2105.
33. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid organ transplant. Lancet 2000: 356: 645.
34. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999: 180: 247.
35. Muheim C, Vogel G, Seydoux C et al. Determinants of protracted cytomegalovirus infection in solid organ transplant patients. Transplantation 2002: 72: 226.
36. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000: 181: 717.
37. Singh N, Wannstedt C, Keyes L et al. Impact of evolving trends in recipient and donor characteristics on cytomegalovirus infection in liver transplant recipients. Transplantation 2004: 77: 106.